stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) Revenue
TransMedics Group, Inc.'s revenue for fiscal 2025 was $605.5M, up 37.1% from $441.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $727.7M. Over the past ten years it has ranged from $6.2M (fiscal 2016) to $605.5M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 9 consecutive fiscal years. TransMedics Group, Inc. ranks 34th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $605.5M | 37.13% |
| FY2024 | $441.5M | 82.74% |
| FY2023 | $241.6M | 158.53% |
| FY2022 | $93.5M | 208.83% |
| FY2021 | $30.3M | 18.03% |
| FY2020 | $25.6M | 8.62% |
| FY2019 | $23.6M | 81.33% |
| FY2018 | $13.0M | 69.38% |
| FY2017 | $7.7M | 23.77% |
| FY2016 | $6.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $203.0M | 6.87% |
| Jun 2026 | $189.9M | 9.21% |
| Mar 2026 | $173.9M | 8.19% |
| Dec 2025 | $160.8M | 11.78% |
| 31 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| NEOG Neogen Corporation compare | $884.0M |
| INSP Inspire Medical Systems, Inc. compare | $880.9M |
| TMDX TransMedics Group, Inc. | $727.7M |
| NVCR NovoCure Limited compare | $725.4M |
| UFPT UFP Technologies, Inc. compare | $649.5M |
| AXGN AxoGen, Inc. compare | $266.9M |
| ESTA Establishment Labs Holdings Inc. compare | $245.8M |
| BFLY Butterfly Network, Inc. compare | $123.3M |
| ALMR Alamar Biosciences, Inc. compare | $105.2M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TMDX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement